Satellos Bioscience (TSE:MSCL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Satellos Bioscience has initiated a Phase 1 clinical trial with the first participant dosed with SAT-3247, a new drug aimed at regenerating muscle in Duchenne muscular dystrophy and other muscle-related conditions. The company expects to collect initial data on safety and pharmacokinetics by Q4 2024 and plans to start trials with DMD patients in early 2025. This marks a significant advancement for Satellos, positioning them as a clinical stage company.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
